MEDBOX | Toolbox ART Drug Resistance

	Guidelines - European AIDS Clinical Society (EACS) European AIDS Clinical Society (EACS) European AIDS Clinical Society (EACS) (2020) C2 Open external link (1706) Add to my MEDBOX Version 10.1_5 October 2020 These Guidelines are available in different formats: As a paper booklet, a PDF, a mobile app, and now also as a website. The 2019 version of the Guidelines introduces a new drug-drug interaction panel and now consists of six main sections, including a general overview table of all major issues in PLWH, recommendations on antiretroviral treatment, drug-drug interactions, diagnosis, monitoring and treatment of co-morbidities, co-infections and opportunistic diseases. Available in English, French, Spanish, German, Portuguese, Russian, Chinese and Japanes Tags: HIV, hiv drugs, hiv treatment, Guidelines, Europe, ART, ARV, STI, Source: https://www.eacsociety.org/guidelines/ea
	HIV drug resistance surveillance in countries scaling up pre-exposure prophylaxis World Health Organization WHO (2020) C_WHO View PDF(25) Download (26) Add to my MEDBOX WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches. HIV drug resistance has been rarely reported among PrEP users who tested HIV positive in randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy Tags: HIV, Surveillance, Drug Resistance, update, hiv surveillance, PEP, PrEP, Source: https://apps.who.int/iris/rest/bitstream
	WHO/HIVRESNET HIV drug resistance - laboratory operational framework World Health Organization WHO (2020) C_WHO View PDF(34) Download (31) Add to my MEDBOX The aim of the operational framework is to ensure 1) accurate collection, handling, shipment and storage of specimens collected in countries implementing HIV drug resistance surveillance; and 2) the availability of quality-assured HIV genotyping laboratory services producing comparable and reliable results at the national, regional and global levels. This publication updates the WHO HIVResNet HIV drug resistance laboratory operational framework published in 2017 and reflects technical and strategic developments over the past three years Tags: laboratory, HIV, Drug Resistance, guideline, Source: https://apps.who.int/iris/rest/bitstream
	WHO manual for HIV drug resistance testing using dried blood spot specimens World Health Organization WHO (2020) C_WHO View PDF(0) Download (0) Add to my MEDBOX HIV-1 drug resistance (HIVDR) genotyping is an essential component of the WHO global HIVDR surveillance strategy. Plasma “gold standard” specimen type for HIVDR genotyping, but its use may not be feasible in rural, remote areas in low- and middle-income countries, since preparing and storing it require personnel and laboratory infrastructure that are often lacking. An alternative specimen type is dried blood spots (DBS), which can be made without special laboratory processing. DBS are more easily transported than plasma because they can be shipped at ambient temperature as non-hazardous materials using regular mail or courier services. 3rd editio Tags: HIV/AIDS, Drug Resistance, dried blood spots, diagnostics, Source: https://apps.who.int/iris/rest/bitstream
	Antiretroviral drugs 2018/19 i-base (2019) C2 View PDF(28) Download (22) Add to my MEDBOX www.i-Base.info Accessed: 28.11.2019 Tags: antiretrovirals, Drugs, HIV, Source: http://i-base.info/guides/wp-content/upl
	HIV drug resistance report 2019 World Health Organization (WHO) World Health Organization (WHO) (2019) C_WHO View PDF(195) Download (99) Add to my MEDBOX WHO/CDS/HIV/19.21 Tags: hiv, hiv treatment, Drug Resistance, annual report, Source: https://apps.who.int/iris/bitstream/hand
	HIV Drug Resistance. Time to act is now S. Bertagnolio World Health Organization WHO (2019) C_WHO View PDF(18) Download (18) Add to my MEDBOX Tags: HIV, Drug Resistance, laboratory, Source: https://www.who.int/hiv/drugresistance/H
	Preventing and responding to HIV drug resistance in the african region World Health Organization WHO (Africa) World Health Organization WHO (Africa) (2019) C_WHO View PDF(28) Download (20) Add to my MEDBOX Regional action plan 2019-2023 Tags: HIV, africa, Drug Resistance, prevention, Source: https://www.afro.who.int/sites/default/f
	Directrices unificadas sobre prevención, diagnóstico, tratamiento y atención de la infección por el VIH para grupos de población clave (Julio 2017) Pan American Health Organization (PAHO) (2019) C_WHO View PDF(145) Download (85) Add to my MEDBOX Tags: hiv drug resistance, Public health, Guidelines, Source: http://iris.paho.org/xmlui/bitstream/han
	Directrices sobre la respuesta de salud pública a la farmacorresistencia del VIH previa al tratamiento. Julio 2017 Pan American Health Organization (PAHO) (2019) C_WHO View PDF(101) Download (60) Add to my MEDBOX Tags: hiv drug resistance, guideline, ART, HIV/AIDS, Source: http://iris.paho.org/xmlui/bitstream/han

About MEDBOX

MEDBOX Video Series